{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.68","upperLimit":"5.42","value":"3.75"},{"groupId":"OG001","lowerLimit":"3.81","upperLimit":"5.62","value":"5.42"},{"groupId":"OG002","lowerLimit":"3.55","upperLimit":"5.59","value":"3.75"},{"groupId":"OG003","lowerLimit":"5.13","upperLimit":"5.75","value":"5.55"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"389"},{"groupId":"OG001","value":"393"},{"groupId":"OG002","value":"153"},{"groupId":"OG003","value":"389"}],"units":"Participants"}],"description":"TTP was defined as the time from randomization until objective tumor progression in the absence of death. If participants died without tumor progression, they were censored at the time of death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Durvalumab 1500 mg every 4 weeks (Q4W)","id":"OG000","title":"Durva 1500 mg"},{"description":"Tremelimumab 300 mg × 1 dose + durvalumab 1500 mg Q4W","id":"OG001","title":"Treme 300 mg x1 Dose + Durva 1500 mg"},{"description":"Tremelimumab 75 mg Q4W × 4 doses + durvalumab 1500 mg Q4W","id":"OG002","title":"Treme 75 mg x4 Doses + Durva 1500 mg"},{"description":"Sorafenib 400 mg twice daily (BID)","id":"OG003","title":"Sora 400 mg"}],"paramType":"MEDIAN","populationDescription":"The FAS included all participants who were randomized. T75+D arm was closed during study.","reportingStatus":"POSTED","timeFrame":"From the date of randomization until objective tumor progression, assessed until the final analysis DCO (27Aug2021, to a maximum of approximately 46 months).","title":"Time To Progression (TTP)","type":"SECONDARY","unitOfMeasure":"months"}